Faculty Member – Howard Hendrickson

Howard Hendrickson, Ph.D. 
Associate Professor

Office: Biomed II, Room 359-2
Lab:  Biomed II, Room 413-2
Phone: 501-603-1547
FAX: 501-526-6599

E-mail: HendricksonHowardP@uams.edu

Research Interests

Exciting challenges exist in the development of high-throughput analytical techniques capable of addressing problems identified by recent advances in the areas of pharmaceutical and drug discovery research. In general, we concern ourselves with improving the speed of analysis beginning with sampling process and ending with the data analysis. Our primary goal is to develop a general approach to analytical methods development that is based the physical and chemical properties of drug candidates. Of particular interest to my research group is the discovery and validation disease markers, through targeted metabolomics.

Teaching

Pharmaceutics
Pharmaceutical Analysis

Recent Publications

Ongoing Research Support

HHSO100201100045C
Hauer-Jensen (PI)
9/13/14 – 9/12/15
Advanced Development of SOM230 as a Radiation Mitigator
The major goal of this project is to develop SOM230 as a radiation mitigator in non-human primates (NHP) as per FDA’s Animal Rule.
Role: Co-I

UAMS TRI Strategic Investment Award
Hendrickson (PI)
Development of Research Grade Goldenseal Phase II
9/1/13 – 8/31/15
The purpose of these studies is to characterize the clinical pharmacokinetics of key alkaloids present in Hydrastis Canadensis following administration of a unique goldenseal extract.
Role: PI

Completed Research Support (last 3 years)

2R44AT003365
Hendrickson (PI), Beavers (PI)
9/1/2011 – 8/31/2014
Development of Research Grade Goldenseal Phase II
The goals of this study were to develop standardized Hydrastis products in research to enable (1) comparisons across studies using the same products, (2) allow for comparisons between known products, and (3) lead to subsequent, large randomized controlled clinical trials. A reliable and constant source for these products will assure the quality of study outcomes.
Role: PI

R21DA031837
Oliveto (PI)
7/1/2011 – 6/30/2014
Impact of CYP2D6 Phenotype on Response to Methamphetamine
The purpose of this study was to examine whether metabolic phenotype impacts behavioral response to methamphetamine.
Role Co-I

R01DA026423
Peterson (PI)
7/1/2009 – 6/30/2013
NIH/NIDA
Antibody-nanoparticle conjugates for the treatment of methamphetamine abuse
Through the combination of molecular biology and nanotechnology, the goals of this study were to create antagonists with customized properties for direct application to methamphetamine-related medical needs like drug overdose and addiction.
Role: Co-I

U01DA023900
Owens (PI)
7/1/2007 – 6/30/2012
NIH/NIDA
Active immunization for treating methamphetamine abuse
The goals of these preclinical studies were to discover and develop new methamphetamine vaccines to help patients stop using these addictive drugs. These important new MCVs are expected to block or reduce methamphetamine effects in patients.
Role: Co-I

Curriculum Vitae